Article
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.
Circulation - 17 Jun 1997
Groenemeijer B E, Hallman M D, Reymer P W, Gagné E, Kuivenhoven J A, Bruin T, Jansen H, Lie K I, Bruschke A V, Boerwinkle E, Hayden M R, Kastelein J J
Abstract excerpt
BACKGROUND: Lipoprotein lipase (LPL) is the rate-limiting enzyme in the lipolysis of triglyceride-rich lipoproteins, and the gene coding for LPL is therefore a candidate gene in atherogenesis. We previously demonstrated that two amino acid substitutions in LPL, the Asn291-Ser and the Asp9-Asn, are associated with elevated triglycerides and lower HDL cholesterol and are present with greater frequency in coronary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.